标本性肥胖和心血管疾病风险和死亡率:系统性审查和元分析
Zhengsheng Zhang1, Xiaolin Zeng2
1Department of Cardiology, The People's Hospital of Pingshan (Pingshan Hospital, Southern Medical University), Shenzhen, China.
Anatolian journal of cardiology
|November 17, 2025
概括
肥胖症显著增加心血管疾病 (CVD) 的风险和死亡率. 这种状况的特点是肌肉质量低和肥胖,构成重大威胁,特别是在男性和特定的心血管事件中.
科学领域:
- 心脏病学 心脏病学
- 老年学是指老年学的学科.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 麻症和肥胖是心血管疾病 (CVD) 的独立风险因素.
- 麻症和肥胖症 (称为麻性肥胖症 (SO)) 对心血管疾病风险和死亡率的综合影响尚未完全理解.
- 这项研究解决了有关SO和心血管结果之间的关联的知识差距.
研究的目的:
- 系统地审查和元分析形肥胖 (SO) 与心血管疾病 (CVD) 风险之间的关联.
- 评估SO对心血管疾病相关死亡率的影响.
- 在SO-CVD关系中识别潜在的效果修饰剂.
主要方法:
- 在主要的科学数据库中进行了全面的文献搜索,截至2025年5月.
- 包括观察性研究,调查SO与发生心血管疾病或心血管疾病死亡率有关.
- 使用随机效应模型计算了聚合赔率比率 (OR),并对各种因素进行了子组分析.
主要成果:
- 分析包括了16项研究,共有578,408名参与者.
- 肥胖与95%的心血管疾病风险增加 (OR=1.95) 和64%的心血管疾病死亡风险增加 (OR=1.64) 有关.
- 对心肌梗塞和心房动观察到更高的风险,按性别和心血管结局类型指出了显著的相互作用.
结论:
- 型肥胖是一种高风险的表型,与心血管疾病发病率和死亡率的增加显著相关.
- SO对心血管结果的影响因性别和心血管事件的特定类型而有所改变.
- 研究结果强调需要标准化诊断标准和针对性干预措施,以减轻SO的心血管风险.
相关概念视频
Coronary Artery Disease I: Introduction
843
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
Psychoneuroimmunology: Cardiovascular Disease
363
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
363
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
149
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
149
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
211
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
211
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290


